Vitamin D3 for Life

Live Enlightened

Article

Circulating Vitamin D Measurements: Physiological and Analytical Limitations: Full Study

Previous related pageChoosing the Correct Vitamin D Biomarker: Clinical Limitations and Misinterpretation Risks: Study SummaryNext related pageCirculating Vitamin D Measurements: Physiological and Analytical Limitations: Study Summary
Study at a glance

Why can vitamin D blood results differ between tests and health conditions?

This page asks why a vitamin D blood result can differ between laboratory methods and health conditions. It reviews laboratory research and studies comparing tests. The main measurement is total 25-hydroxyvitamin D, the usual blood marker of vitamin D levels. This total should include the forms made from both vitamin D2 and vitamin D3.

Why did laboratory methods give different vitamin D results?

Some automated tests did not fully measure the form made from vitamin D2. Tests can also differ in how they separate vitamin D from carrier proteins or distinguish it from similar substances. More detailed laboratory methods can separate these forms, but they still need careful checking. Two tests can follow the same pattern while consistently giving different numbers.

Can season, illness and body size affect a vitamin D blood result?

Season, illness, body size and changes in carrier proteins can affect blood measurements. A result may accurately describe the blood sample without describing vitamin D levels over a longer period. A blood result also does not directly measure how vitamin D acts inside tissues.

Do these limits make the usual vitamin D blood test less useful?

Total 25-hydroxyvitamin D remains a useful test, but the laboratory method and the person’s circumstances matter. These limits do not mean that every low result is an error or that routine tests are useless. The evidence does not show that any method removes all uncertainty or that free vitamin D testing should replace total testing for everyone.

Read the full article below ↓

A vitamin D blood result looks like a single number, but the number is produced by several layers of biology and measurement. The laboratory must first decide which vitamin D metabolite is being measured, then recover that analyte from binding proteins, distinguish it from related metabolites, calibrate the assay and report a concentration that is interpreted against clinical thresholds. Each layer can introduce limitations. The most widely used status marker, total circulating 25-hydroxyvitamin D [25(OH)D], remains the best general biochemical indicator of vitamin D status, but it is not a direct measurement of vitamin D action in tissues and it is not analytically identical across every method or patient group.

The first limitation is defining the measurand

Vitamin D is not one circulating molecule. Vitamin D3 formed in skin or taken orally is converted to 25(OH)D3, while vitamin D2 from ergocalciferol can produce 25(OH)D2. Both can contribute to vitamin D status, so a total 25(OH)D result should represent the sum of the clinically relevant D2 and D3 25-hydroxy forms. That requirement sounds simple, but it immediately creates an analytical problem: an assay must either measure both forms equimolarly or separate and quantify them before summing them. If it responds differently to 25(OH)D2 and 25(OH)D3, the reported total can depend partly on which form of vitamin D a person receives rather than only on the underlying amount present in circulation.

The measurand is also threatened by structurally related metabolites. The C3 epimer of 25(OH)D3 has the same nominal mass as 25(OH)D3 and can be included in some mass-spectrometric measurements unless chromatography separates it. Conversely, automated immunoassays can show variable cross-reactivity with other vitamin D metabolites. The practical point is not that one platform always reads high and another always reads low. It is that the meaning of “total 25(OH)D” depends on whether the method is actually measuring the intended molecular population.

Binding proteins make extraction part of the measurement

Most circulating 25(OH)D is bound to vitamin D-binding protein and a smaller fraction to albumin; only a very small fraction is free. Routine total-25(OH)D assays therefore have to recover the analyte from its protein-bound state before it can be quantified. Automated assays use proprietary release chemistry. If release from vitamin D-binding protein is incomplete or behaves differently across sample matrices, the result can be biased even when the antibody or detector itself is functioning as designed.

This is one reason matrix effects matter. Serum is not an inert solvent. Concentrations of binding proteins, lipids, albumin and other constituents vary between people and clinical states. Direct automated assays are especially dependent on release and reaction conditions, while chromatography-based methods usually include extraction and separation steps. The analytical problem therefore includes not only detector specificity but also how successfully the assay prepares a biologically complex sample for measurement.

Automated assays trade convenience for some analytical vulnerability

Automated immunoassays are fast, scalable and practical for routine clinical laboratories. Those advantages explain why they remain widely used. They can perform well in many ordinary samples, and modern systems have improved substantially. That is an important counterweight to any claim that immunoassay vitamin D testing is inherently unreliable.

However, method-comparison studies show that acceptable overall correlation does not make assays interchangeable. Bias can remain at concentrations near decision thresholds; different platforms can classify the same sample differently; and recovery of 25(OH)D2 can be substantially weaker than recovery of 25(OH)D3. In a study that challenged two automated assays after a large vitamin D2 dose, measured 25(OH)D2 recovery was markedly incomplete compared with LC-MS/MS. This matters most when ergocalciferol contributes materially to the circulating pool. A person may therefore appear to have a lower total 25(OH)D result because of assay response rather than because all biologically relevant 25-hydroxyvitamin D is absent.

LC-MS/MS is more specific, not infallible

Liquid chromatography-tandem mass spectrometry can distinguish 25(OH)D2 from 25(OH)D3, quantify multiple metabolites and, when appropriately developed, provide higher analytical specificity than most automated immunoassays. It is therefore widely treated as the preferred or reference-oriented approach for complex measurement. But calling LC-MS/MS a gold standard must not be turned into the claim that every LC-MS/MS result is automatically correct.

Mass spectrometry still depends on calibration, extraction, chromatography, internal standards, instrument settings, validation and operator expertise. If the chromatographic system does not resolve isobaric epimers, an analytically specific mass detector can still count the wrong molecular species. Different laboratories can also implement different methods. Standardisation and traceability remain relevant even for LC-MS/MS, and certified reference materials do not substitute for competent method development and quality assurance.

Standardisation reduces variability but does not erase interpretation

International standardisation programmes, reference measurement procedures, NIST materials and external quality-assessment schemes have improved comparability. They are crucial because historical assay drift and between-laboratory differences could change apparent population prevalence of “deficiency” or move individuals across decision thresholds. Standardisation narrows one layer of uncertainty: whether two laboratories are measuring the same intended quantity on a comparable scale.

It cannot solve a different problem: whether the measured circulating quantity is the complete biological answer. A perfectly standardised total 25(OH)D measurement is still a concentration in blood. It does not directly report tissue uptake, local conversion to 1,25-dihydroxyvitamin D, receptor response, intracellular signalling or downstream biological effect. That distinction is central to understanding Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D: choosing the correct metabolite is a separate question from measuring that metabolite accurately.

Physiological variation can change what a circulating concentration represents

Even when the analytical number is correct, the relationship between circulating concentration and the body’s wider vitamin D state can vary. Binding-protein concentration changes in pregnancy, liver disease and protein-losing states can alter the partitioning of total and free vitamin D metabolites. Obesity is associated with lower circulating 25(OH)D concentrations and a smaller rise after equivalent exposure or supplementation, with volumetric dilution among the leading explanations. Acute illness can change fluid distribution, albumin and binding proteins and may alter measured 25(OH)D independently of a simple change in long-term vitamin D input.

These are physiological limitations, not necessarily laboratory errors. An assay can correctly report the concentration present in the specimen while the clinician still misinterprets what that concentration means for longer-term status or functional availability. This is why analytical validity and physiological interpretation must be kept separate.

A single number also contains ordinary biological variation

Circulating 25(OH)D is dynamic. Sun exposure, season, recent supplementation, body composition and changing physiology all contribute to within-person variation. A result taken near the end of summer can represent a different point on an annual trajectory from a result taken near the end of winter. In older adults, one large cohort found a substantial seasonal peak-to-trough difference, large enough for a single measurement to misclassify estimated longer-term exposure.

That issue connects directly with Biological Noise in Vitamin D Testing and Variability in Vitamin D Measurements. The analytical method may be stable while the biology being sampled is moving. Serial results therefore need to be interpreted against both expected biological variation and possible analytical variation rather than treating every numerical change as a true change in underlying physiology.

Why good correlation does not mean interchangeability

Method-comparison studies often report strong correlations between assays. That can sound reassuring, but correlation answers a narrower question than clinical interchangeability. Two methods can rank samples in almost the same order while one reports values systematically higher or lower than the other. If clinical decisions use fixed concentration thresholds, a persistent bias can change classification even when correlation is excellent. Agreement analysis, calibration traceability and performance around medical decision points therefore matter more than a correlation coefficient alone.

This distinction also explains why an assay can be broadly useful at population level yet problematic for an individual near a cut-off or in a sample containing an unusual metabolite mixture. The existence of method limitations should not be exaggerated into universal failure, but neither should good average performance be used to erase clinically relevant outliers or subgroup effects.

What the evidence supports

The strongest evidence supports a layered interpretation. Total 25(OH)D remains the most useful general marker of vitamin D status, but the reported value is conditional on the intended measurand, assay design, extraction from binding proteins, cross-reactivity, metabolite separation, calibration and standardisation. LC-MS/MS usually provides greater specificity and metabolite resolution, but it still requires appropriate chromatography, calibration and laboratory validation. Automated assays can be suitable for routine use but may perform less well in particular sample types, especially where 25(OH)D2 contributes materially.

Above the analytical layer sits a physiological layer. A blood concentration is a circulating compartment measurement, not a direct assay of tissue action. Changes in binding proteins, body size, fluid shifts, illness and season can change the relationship between the measured number and the biological question being asked. The safest interpretation is therefore neither “vitamin D blood tests are useless” nor “the number is the body’s vitamin D truth.” The test is informative when the correct marker, method and clinical context are understood together.

Evidence boundaries

The reviewed evidence does not establish that every low 25(OH)D result is an assay artefact, that immunoassays should never be used, or that free 25(OH)D should routinely replace total 25(OH)D. It also does not show that LC-MS/MS eliminates all uncertainty. Method performance differs by platform and laboratory, and physiological modifiers do not operate identically in every patient. A limitation should therefore be treated as a reason to interpret carefully, not as permission to dismiss an inconvenient result.

Primary source and publication details

Supporting analytical evidence includes Xie Z and colleagues’ method-comparison study of automated immunoassays and LC-MS/MS, and the IFCC position paper on vitamin D metabolite and binding-protein measurement. These were used to test the review’s analytical claims and identify method-specific boundaries rather than to imply that every platform performs identically.

Study Summary

For the shorter reader route, see Circulating Vitamin D Measurements: Physiological and Analytical Limitations: Study Summary.

Related reading

Original sources

Source

Read the full study

Dirks NF, Cavalier E, Heijboer AC.

Publication details

Dirks NF, Cavalier E, Heijboer AC. Vitamin D: marker, measurand & measurement. Endocrine Connections. 2023;12(4):e220269. PMID: 36688810. PMCID: PMC10083657. DOI: 10.1530/EC-22-0269. Read the full study.

Read more →